Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Real-time quantitative PCR analysis of celecoxib treatment on OC tissue chip

ABSTRACT: To test the utility of iPSC-derived OC tissue chip in drug screening, Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor commonly used to treat OA, was administered to the system. Celecoxib was administered at 10 µM concentration, and showed no noticeable adverse effect on the health of normal chondral tissue. Administration of Celecoxib to both OC-C and OC-B were used to simulate the typically systemic action of Celecoxib, represented by the “SY” group. In addition, we also examined the potential effect of intraarticular (IA) application of Celecoxib in treating OA, by delivery only to OC-C, namely the “IA” group. Normal OC tissues without any treatments served as the control (CL).

ORGANISM(S): Homo sapiens

PROVIDER: GSE140336 | GEO | 2019/11/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Real-time quantitative PCR analysis of OC-C and CH under osteoarthritic condition

Project description:IL-1β (1 ng/ml) was introduced via medium feed to the cartilage side to induce OA-like phenotype in both OC and CH tissue chip. The catabolic, inflammatory and chondrogenic gene expression were compared between these two groups to assess the effect of osseous tissue on chondral tissue under OA condition.

2019-11-14 | GSE140335 | GEO

Real-time quantitative PCR analysis of celecoxib treatment on OC tissue chip

Project description:Real-time quantitative PCR analysis of celecoxib treatment on OC tissue chip

| PRJNA589302 | ENA

Chemoprevention of the hepatocarcinogenesis by celecoxib

Project description:Microarray analysis is a useful methodology to identify target genes modulated by anticancer drugs. Here, celecoxib effect on gene expression profiles was evaluated in the modified resistant hepatocyte model. Animals subjected to carcinogenic treatment were fed with diet containing 1500 ppm of celecoxib. Two schemes of celecoxib administration were designed. In the progression protocol, celecoxib was administrated between days 18 and 25 post-cancer initiation, a total of 8 celecoxib treatment days, when well established preneoplastic lesions starts to appear. In the initiation protocol, celecoxib was administrated from one week before until 25 days after of cancer initiation, a total of 32 celecoxib treatment days. A rat group was subjected only to the carcinogenic treatment as cancer positive control. Gene expression profiles of all groups were compared to a negative untreated control. The evaluation of gene expression profiles permitted us to identify new target genes that are modulated by celecoxib treatment. A possible mechanism of celecoxib chemoprevention of hepatocarcinogenesis is proposed.

2009-07-10 | GSE12112 | GEO

Chemoprevention of the hepatocarcinogenesis by celecoxib

2009-07-10 | E-GEOD-12112 | biostudies-arrayexpress

Rat cardiomyocyte; control vs celecoxib treatment

Project description:Gene expression analysis of celecoxib-treated rat cardiomyocytes vs non-treated rat cardiomyocytes. Goal of study is to identify changes on genes expression induced by celecoxib. The data analysis focused on genes that might be related to cardiotoxicity; genes expression ion channels and pathways. two control samples vs 6 celecoxib-treated samples. Variables of treatment included two time points (6h or 24h) and three reference concentrations (1, 1/5 and 1/25). Each group had 3 replicates.

2016-02-05 | E-GEOD-77591 | biostudies-arrayexpress

Rat cardiomyocyte; control vs celecoxib treatment

2016-02-05 | GSE77591 | GEO

Celecoxib induced transcriptional alterations in gastric cancer cells

2014-04-01 | GSE54657 | GEO

Celecoxib induced transcriptional alterations in gastric cancer cells

Project description:Celecoxib is recognized to have chemopreventive and anti-cancer property beyond its anti-inflammatory function. Celelcoxib treatment in AGS cells down regulates Wnt/M-NM-2-catenin, STAT3, RXR and ERK/MAPK signaling pathways. Transcriptional profiling after celecoxib shows differential regulation of oncogenic pathway regulated genes. AGS cell were treated with celecoxib in triplicates and incubated for 24 hours. The processed samples were hybridized in M-bM-^@M-^\HuGene-1_0-stM-bM-^@M-^] array and the differentially expressed genes were taken for pathway analysis and transcription factor enrichment analysis.

2014-04-01 | E-GEOD-54657 | biostudies-arrayexpress

Expression data from human OC+BAP+ double positive versus OC-BAP- double negative cells

Project description:Subpopulation of circulating monocyte/macrophage lineage cells show a calcifying ability in vivo and in vitro. These cells may contribute to intimal calcification within atherosclerotic lesions and may have pathophysiological clinical and therapeutic implication in vascular disorders. Such cells express Osteocalcin (OC) and Bone Alkaline Phosphatase (BAP). We analysed the expression profile of human OC+BAP+ cells versus OC-BAP- cells

2013-05-17 | GSE47060 | GEO

Celecoxib, Rofecoxib Gavage Treated Mice, Aorta RNA-Seq

Project description:Celecoxib, Rofecoxib Gavage Treated Mice, Aorta RNA-Seq

2020-03-07 | GSE97066 | GEO